Health
Partnership to develop head and neck cancer vaccine – Mirage News
Professor Christian Ottensmeier (centre)Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company)…
Professor Christian Ottensmeier (centre)
Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company) have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the UK die each year. Whilst exis…
-
Business19 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News18 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General13 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News15 hours agoTips to improve engagement – Proctor